IEX •
Healthcare •
Biotechnology •
Quote as of 09/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization15.73 mln
Earnings Date11/13/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-5.66
Highly reliable
1-Year Forecast
56.00
Transformational upside
Relative Strength
4
/ 100
Severely lagging
Pre-Tax Margin
-353%
Severely loss-making
ROE
-85.83
Deeply negative
Business Description
Cyclerion Therapeutics is a Cambridge, Massachusetts-based drug development company focused on treating serious conditions affecting the heart, kidneys, and nervous system. The company is advancing two key drug candidates: Olinciguat, currently in Phase 2 trials for cardiovascular disease, and Praliciguat, aimed at treating rare kidney conditions. Cyclerion has partnered with Akebia Therapeutics to develop, manufacture, and commercialize Praliciguat and related treatments. Founded in 2018, the company applies its expertise in a specific class of molecules known as sGC stimulators to address diseases with limited treatment options.
